UK cancer firm AVO buys Large Hadron Collider spin-off However, it costs hospitals £120m for a proton beam therapy machine and treating a patient can cost between £90,000 and £120,000 each, although the introduction of more compact accelerators in the machines could bring down the cost. Lord Evans of Watford, chairman of AVO, said: "Our strategy to establish AVO as a leading provider of convenient, cost-effective and clinically superior treatment to patients with cancer, based on proven technologies, will move forward significantly with the acquisition of Adam. Adam's management team are well known to us and share our vision of introducing disruptive technology - that will change cost models - to fast growing cancer treatment markets. The deal will see AVO acquire 100pc of Adam's share capital in exchange for a 29.9pc stake in AVO. The arrangement - based on yesterday's opening prices, values the acquisition at £1.3m Shares in AVO rose 30pc to 1.45p in afternoon trading on Wednesday.